122 related articles for article (PubMed ID: 3002594)
1. Vindesine and mitomycin C in chemotherapy: refractory advanced breast cancer.
Di Costanzo F; Gori S; Tonato M; Buzzi F; Crino L; Grignani F; Davis S
Cancer; 1986 Mar; 57(5):904-7. PubMed ID: 3002594
[TBL] [Abstract][Full Text] [Related]
2. Combination chemotherapy with mitomycin C, vindesine and melphalan for refractory metastatic breast cancer.
Rausa L; Russo A; Gebbia V; Gebbia N; D'Alessandro N; Palmeri S
J Cancer Res Clin Oncol; 1991; 117(3):266-8. PubMed ID: 1709643
[TBL] [Abstract][Full Text] [Related]
3. Treatment of advanced breast cancer with mitomycin C combined with vinblastine or vindesine.
Garewal HS; Brooks RJ; Jones SE; Miller TP
J Clin Oncol; 1983 Dec; 1(12):772-5. PubMed ID: 6422004
[TBL] [Abstract][Full Text] [Related]
4. [A study of VMMC protocol (vindesine, mitoxantrone, mitomycin C) as a salvage chemotherapy in advanced breast cancers].
Degardin M; Hecquet B; Bonneterre J; Adenis A; Pion JM; Demaille A
Bull Cancer; 1992; 79(2):169-76. PubMed ID: 1392155
[TBL] [Abstract][Full Text] [Related]
5. Vindesine and mitomycin C in metastatic breast cancer. A Southeastern Cancer Study Group Trial.
Lyss AP; Luedke SL; Einhorn L; Luedke DW; Raney M
Oncology; 1989; 46(6):357-9. PubMed ID: 2511534
[TBL] [Abstract][Full Text] [Related]
6. Long duration of response with vindesine-mitoxantrone-mitomycin (VMMc) combination chemotherapy in metastatic breast cancer: a pilot phase II study.
Belpomme D; Heritier F; Gisselbrecht C; Marty M; Michaud G; Le Rol A; Cour V; George C; Maral J
Cancer Treat Rep; 1987 Sep; 71(9):845-7. PubMed ID: 3621218
[TBL] [Abstract][Full Text] [Related]
7. Failure of mitomycin-vindesine combination chemotherapy as salvage treatment for metastatic breast cancer.
Ardizzoni A; Pronzato P; Canobbio L; Lionetto R; Rosso R
J Cancer Res Clin Oncol; 1985; 110(1):77-8. PubMed ID: 4019571
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin, vindesine, mitomycin-C and 13-cis retinoic acid in the treatment of advanced non small cell lung cancer. A phase II pilot study.
Recchia F; Sica G; De Filippis S; Rosselli M; Saggio G; Guerriero G; Pompili P; Rea S
Anticancer Res; 2000; 20(3B):1985-90. PubMed ID: 10928138
[TBL] [Abstract][Full Text] [Related]
9. [Salvage chemotherapy with mitomycin C and vindesine in metastatic carcinoma of the breast].
Ardizzoni A; Lionetto R; Repetto L; Pronzato P; Rosso R
G Ital Chemioter; 1985; 32(1):61-2. PubMed ID: 3938418
[No Abstract] [Full Text] [Related]
10. Trial of vindesine plus mitomycin in stage-3 non-small cell lung cancer. An active regimen for outpatient treatment.
Kris MG; Gralla RJ; Kelsen DP; Casper ES; Burke MT; Fiore JJ; Cibas IR; Heelan RT
Chest; 1985 Mar; 87(3):368-72. PubMed ID: 2982552
[TBL] [Abstract][Full Text] [Related]
11. High-dose medroxyprogesterone acetate plus mitomycin-C or vindesine in the treatment of advanced breast cancer.
Falkson CI; Falkson HC; Falkson G
Am J Clin Oncol; 1988 Aug; 11(4):431-4. PubMed ID: 2970218
[TBL] [Abstract][Full Text] [Related]
12. [Combination chemotherapy including cisplatinum, vindesine and mitomycin C for non-small cell lung cancer].
Hayashi Y; Kato M; Matsuura T; Yamada Y; Adachi S; Ito G; Yamamoto K; Takeuchi T
Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1455-60. PubMed ID: 2167632
[TBL] [Abstract][Full Text] [Related]
13. A randomized study of two vindesine plus cisplatin-containing regimens with the addition of mitomycin C or ifosfamide in patients with advanced non-small cell lung cancer.
Rosell R; Abad-Esteve A; Moreno I; Barnadas A; Carles J; Fernandez C; Ribelles N; Culubret M
Cancer; 1990 Apr; 65(8):1692-9. PubMed ID: 2156597
[TBL] [Abstract][Full Text] [Related]
14. Low-dose mitomycin and weekly low-dose doxorubicin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, and 5-fluorouracil.
Colozza M; Tonato M; Grignani F; Davis S
Cancer; 1988 Jul; 62(2):262-5. PubMed ID: 3383126
[TBL] [Abstract][Full Text] [Related]
15. Comparison of vindesine plus cisplatin or vindesine plus mitomycin in the treatment of advanced non-small cell lung cancer.
Shinkai T; Saijo N; Tominaga K; Eguchi K; Shimizu E; Sasaki Y; Fujita J; Futami H
Cancer Treat Rep; 1985 Sep; 69(9):945-51. PubMed ID: 2992785
[TBL] [Abstract][Full Text] [Related]
16. Extensive non-small cell lung cancer treated with mitomycin, cisplatin, and vindesine (MiPE): a Southwest Oncology Group Study.
Miller TP; Vance RB; Ahmann FR; Rodney SR
Cancer Treat Rep; 1986 Sep; 70(9):1101-4. PubMed ID: 3527409
[TBL] [Abstract][Full Text] [Related]
17. Phase III trial with and without lonidamine in non-small cell lung cancer.
Gatzemeier U; Cavalli F; Häussinger K; Kaukel E; Koschel G; Martinelli G; Neuhauss R; von Pawel J
Semin Oncol; 1991 Apr; 18(2 Suppl 4):42-8. PubMed ID: 1851577
[TBL] [Abstract][Full Text] [Related]
18. [A randomized trial comparing vindesine plus cisplatin with mitomycin C, vindesine plus cisplatin in patients with advanced non-small cell lung cancer].
Fujii M; Kiura K; Okabe K; Toki H; Kimura M
Gan To Kagaku Ryoho; 1987 Sep; 14(9):2676-81. PubMed ID: 2820312
[TBL] [Abstract][Full Text] [Related]
19. Mitomycin-C, vinblastine, and lonidamine as salvage treatment of advanced breast cancer. A pilot study.
Zaniboni A; Montini E; Simoncini E; Marpicati P; Arcangeli G; Meriggi F; Marini G
Am J Clin Oncol; 1990 Dec; 13(6):520-3. PubMed ID: 2122716
[TBL] [Abstract][Full Text] [Related]
20. [Prolonged remissions induced by the combination vindesine, mitoxantrone, mitomycine C in metastatic breast cancers].
Belpomme D; Cour V; Gisselbrecht C; Le Rol A; Mignot L; Marty M; Godeffroy W; Maral J
Presse Med; 1987 Apr; 16(13):635. PubMed ID: 2952982
[No Abstract] [Full Text] [Related]
[Next] [New Search]
